CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease: A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Haematologica

Volumn 81, Issue 6, 1996, Pages 503-512

  Gobbi, Paolo G ^a   Pieresca, Carla ^a   Cavanna, Luigi ^b   Corbella, Franco ^c   Vallisa, Daniele ^b   Federico, Massimo ^d   Formisano, Rosanna ^a   Carotenuto, Mario ^e   Merli, Francesco ^f   Callea, Vincenzo ^g   Angrilli, Francesco ^h   Silingardi, Vittorio ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b Ospedale Civile di Piacenza   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f S MARIA NUOVA HOSPITAL   (Italy)

^g BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^h Div Chemio Immunoterapia O   (Italy)

Author keywords

Early stages; Hodgkin's disease; Multiple drug chemotherapy; Radiotherapy; Unfavorable prognosis

Indexed keywords

LOMUSTINE; PREDNISONE; PROCARBAZINE; VINBLASTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ITALY; LEUKOPENIA; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; LOMUSTINE; MALE; MECHLORETHAMINE; MIDDLE AGED; PREDNISONE; PROCARBAZINE; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; VINBLASTINE; VINCRISTINE;

EID: 0030323813     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Urba WJ, Longo DL. Hodgkin's disease. N Engl J Med 1992; 326:678-87.
2. Straus DJ. Modern treatment approaches for Hodgkin's disease. Curr Opin Oncol 1993; 5:785-90.
3. DeVita VT, Hubbard SM. Hodgkin's disease. N Engl J Med 1993; 328:560-5.
4. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295-306.
5. Hoppe RT, Coleman CN, Cox RS, et al. The management of stage 1-11 Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 1982; 59:455-65.
6. Cosset JM, Henry-Amar M, Carde P, et al. The prognostic significance of large mediastinal masses in the treatment of Hodgkin's disease. The experience of the Institut Gustave-Roussy. Hematol Oncol 1984; 2:33-43.
7. Mauch PM, Gorshein D, Cunningham G, et al. Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease. Cancer Treat Rep 1982; 66: 809-17.
8. Liew KH, Eaton D, Horwich A, et al. Bulky mediastinal Hodgkin's disease management and prognosis. Hematol Oncol 1984; 2:45-59.
9. Canellos GP. Can MOPP be replaced in the treatment of advanced Hodgkin's disease? Semin Oncol 1990; 17(Suppl 2):2-6.
10. Nissen NI, Pajak TF, Glidewell O, et al. A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease. A cooperative study by the Cancer and Leukemia Group B. Cancer 1979; 43:31-40.
11. Harrison DT, Neiman PF. Primary treatment of disseminated Hodgkin's disease with BCNU alone and in combination with vincristine, procarbazine, and prednisone. Cancer Treat Rep 1977; 61:789-95.
12. Bakemeier RF, Anderson JR, Costello W, et al. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Ann Intern Med 1984; 101:447-56.
13. Cooper MR, Pajak TF, Nissen NI, et al. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosurea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer 1980; 46:654-62.
14. Tseng A Jr, Jacobs C, Coleman CN, et al. Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate. Cancer Treat Rep 1987; 71:475-8.
15. Lennard AL, Proctor SJ, Dawson AA, et al. Lomustine, vindesine and bleomycin (LVB) used in the treatment of relapsed advanced Hodgkin's disease. A prospective study of the East of Scotland and Newcastle Lymphoma Group (ESNLG). Hematol Oncol 1989; 7: 77-86.
16. Lambertenghi-Deliliers G, Baldini L, Radaelli F, et al. Efficacia terapeutica della polichemioterapia CcVPP nel morbo di Hodgkin. In: Mauri C, Silingardi V Federico M, eds. La malattia di Hodgkin. Recenti acquisizioni e problemi aperti. Modena:Mucchi ed, 1987:201-7.
17. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a Committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting. J Clin Oncol 1989; 7:1630-6.
18. Carbone PP, Spurr C. Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloid. Cancer 1968; 28:98-103.
19. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987; 14:65-74.
20. DeVita VT jr, Hubbard SM, Longo DL. The chemotherapy of lymphoma: looking back, moving forward - The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1987; 47:5810-24.
21. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:129-37.
22. nd ed. Oxford:Blackwell Scientific Publ, 1987, 186-205 and 411-6.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
24. Henry-Amar M, Aeppli DM, Anderson J, et al. Workshop statistical report. In: Somers R, Henry-Amar M, Meerwald JK, Carde P, eds. Treatment strategy in Hodgkin's disease. London: John Libbey Eurotext, 1990:169-422.
25. Gobbi PG, Comelli M, Grignani GE, et al. Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. Haematologica 1994; 79:241-55.
26. Gobbi PG, Pieresca C, Frassoldati A, et al. Vinblastine, bleomycin and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio del Linfomi Experience. J Clin Oncol 1996; 14:527-33.
27. Gobbi PG, Pieresca C, Federico M, et al. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group. J Clin Oncol 1973; 11:712-9.
28. Goldman JM, Dawson AA. Combination therapy for advanced resistant Hodgkin's disease. Lancet 1975; 2:1225-7.
29. Wiernick PH, Schiffer CA. Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB). J Cancer Res Clin Oncol 1988; 114:105-7.
30. Miggiano MC, Gherlinzoni F, Visani G, et al. Hematological recovery after autologous bone marrow transplantation for high-grade non Hodgkin's lymphomas: a single center experience. Haematologica 1994; 79:225-32.
31. Dotti G, Carlo-Stella C, Mangoni L, et al. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy. Haematologica 1995; 80:142-5.